Following the successful completion and review of laboratory studies data for the pre-exposure use of AverTox to protect against exposure to lethal levels of soman, sarin and VX, an additional $981,000 in SBIR grant money has been awarded to Countervail. These funds will be used to continue the development of AverTox toward and eventual NDA submission.